ImmuneOnco Biopharmaceuticals (Shanghai) Past Earnings Performance
Past criteria checks 0/6
ImmuneOnco Biopharmaceuticals (Shanghai)'s earnings have been declining at an average annual rate of -3.4%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 14.1% per year.
Key information
-3.4%
Earnings growth rate
0.6%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 14.1% |
| Return on equity | -62.4% |
| Net Margin | -5,135.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ImmuneOnco Biopharmaceuticals (Shanghai) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 7 | -374 | 69 | 283 |
| 31 Mar 24 | 7 | -377 | 75 | 287 |
| 31 Dec 23 | 8 | -379 | 80 | 292 |
| 30 Sep 23 | 8 | -371 | 84 | 291 |
| 30 Jun 23 | 6 | -362 | 87 | 289 |
| 31 Mar 23 | 6 | -382 | 90 | 283 |
| 31 Dec 22 | 6 | -403 | 93 | 277 |
| 31 Dec 21 | 14 | -733 | 48 | 176 |
Quality Earnings: 1541 is currently unprofitable.
Growing Profit Margin: 1541 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1541's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1541's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1541 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).
Return on Equity
High ROE: 1541 has a negative Return on Equity (-62.37%), as it is currently unprofitable.